WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of the
initial Quell® study in the Journal of Pain Research. The
paper is titled "Fixed-Site High-Frequency Transcutaneous Electrical
Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity
Pain." It is available on-line at:
Journal
of Pain Research - Quell Study
About Quell
Quell is FDA cleared and designed for the millions of people suffering
from chronic pain. The advanced wearable technology delivers 100% drug
free relief and is available without a prescription. Quell can be used
during the day while active, and at night while sleeping. Quell gives
users the option to start, stop, and adjust therapy discreetly via their
smartphone. It also enables advanced sleep tracking. Quell is available
at select healthcare professionals and retailers. To find a Quell
retailer, visit the Store
Locator at QuellRelief.com.
About NeuroMetrix
NeuroMetrix is an innovative healthcare company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160706005021/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
